{"status": "ok", "totalResults": 399, "articles": [{"source": {"id": "the-guardian-au", "name": "The Guardian (AU)"}, "author": "Jamie Doward", "title": "Cost of lifesaving heroin withdrawal drug soars by 700%", "description": "Treatment agencies warn of extra drug-related deaths unless price hike is addressed A 700% spike in the price of a drug used to wean addicts off heroin has caused alarm among treatment agencies, which warn of a rise in drug-related deaths unless urgent action\u2026", "url": "https://www.theguardian.com/politics/2018/sep/29/heroin-withdrawal-generic-drug-price-hike", "urlToImage": "https://i.guim.co.uk/img/media/87252f8d32fd907df11fd163f38f16f4cb4e9156/0_249_5000_3000/master/5000.jpg?width=1200&height=630&quality=85&auto=format&fit=crop&crop=faces%2Centropy&bm=normal&ba=bottom%2Cleft&blend64=aHR0cHM6Ly9hc3NldHMuZ3VpbS5jby51ay9pbWFnZXMvb3ZlcmxheXMvZjZlYzA2YWNlZGUwZWRmMDNiMDM3MmE1Y2VkZWJmZTIvdG8tZGVmYXVsdC5wbmc&s=3cdc1d2d388e4e241235b379d44e2b5a", "publishedAt": "2018-09-29T13:00:25Z", "content": "A 700% spike in the price of a drug used to wean addicts off heroin has caused alarm among treatment agencies, which warn of a rise in drug-related deaths unless urgent action is taken to make it more affordable. Buprenorphine is an alternative to methadone t\u2026 [+4049 chars]"}, {"source": {"id": "the-times-of-india", "name": "The Times of India"}, "author": "ETMarkets.com", "title": "Pharma stks up; Sun Pharma, Lupin top gainers", "description": "The Nifty Pharma index was trading 1.68 per cent up at 10,163 at 10:35 am, with all components in the green zone.", "url": "https://economictimes.indiatimes.com/markets/stocks/news/share-market-update-pharma-stocks-rise-up-to-4-aurobindo-pharma-sun-pharma-lupin-top-gainers/articleshow/65944686.cms", "urlToImage": "https://img.etimg.com/thumb/msid-65944693,width-1070,height-580,imgsize-133450,overlay-etmarkets/photo.jpg", "publishedAt": "2018-09-25T05:03:02Z", "content": "NEW DELHI: Most pharma stocks were trading with gains during Tuesday's session even as broader market sentiment was wobbly. The Nifty Pharma index was trading 1.68 per cent up at 10,163 at 10:35 am, with all components in the green zone. Aurobindo Pharma (up \u2026 [+879 chars]"}, {"source": {"id": "the-times-of-india", "name": "The Times of India"}, "author": "ETMarkets.com", "title": "Pharma stks rise 4%; Aurobindo, Sun in focus", "description": "The Nifty Pharma index was trading 2.43 per cent up at 10,644 around 10:45 am.", "url": "https://economictimes.indiatimes.com/markets/stocks/news/stock-market-update-pharma-stocks-jump-up-to-4-aurobindo-pharma-sun-pharma-hog-limelight/articleshow/65804995.cms", "urlToImage": "https://img.etimg.com/thumb/msid-65805018,width-1070,height-580,imgsize-27371,overlay-etmarkets/photo.jpg", "publishedAt": "2018-09-14T05:14:10Z", "content": "NEW DELHI: Most pharma stocks were trading in the positive territory during Friday's session, giving a boost to the sectoral index. The Nifty Pharma index was trading 2.43 per cent up at 10,644 around 10:45 am on Friday with all components in the green. Aurob\u2026 [+1184 chars]"}, {"source": {"id": null, "name": "Freakonomics.com"}, "author": "Stephen J. Dubner", "title": "Is the Government More Entrepreneurial Than You Think? (Ep. 348)", "description": "We all know the standard story: our economy would be more dynamic if only the government would get out of the way. The economist Mariana Mazzucato says we\u2019ve got that story backward. She argues that the government, by funding so much early-stage research, is \u2026", "url": "http://freakonomics.com/podcast/mariana-mazzucato/", "urlToImage": "http://freakonomics.com/wp-content/uploads/2018/09/The_U.S._Capitol_Building_Washington_D.C.jpg", "publishedAt": "2018-09-06T03:00:35Z", "content": "GPS, touch-screen displays, and the Internet are just a few of the technologies that got early-stage funding from the U.S. Government. (Photo: Andrew Van Huss /Wikimedia Commons) Our latest Freakonomics Radio episode is called \u201cIs the Government More Entrepre\u2026 [+31563 chars]"}, {"source": {"id": "the-times-of-india", "name": "The Times of India"}, "author": "ET Now", "title": "Bullish on these 2 stocks in defence sector: Sanjiv Bhasin", "description": "Pharma basket should be an outperformer as a proxy to a weak rupee and better generic pricing in 2019.", "url": "https://economictimes.indiatimes.com/markets/expert-view/bullish-on-these-2-stocks-in-defence-sector-sanjiv-bhasin-india-infoline/articleshow/65698096.cms", "urlToImage": "https://img.etimg.com/thumb/msid-65698196,width-1070,height-580,imgsize-173374,overlay-etmarkets/photo.jpg", "publishedAt": "2018-09-06T06:38:45Z", "content": "Reducing margins from 12.5% to 7.5% for projects given to defence PSUs suddenly is a draconian step, Sanjiv Bhasin, Executive VP-Markets &amp; Corporate Affairs, India Infoline, tells ET Now. Bhasin expects huge upside in Bharat Forge and L&amp;T. Edited exce\u2026 [+3409 chars]"}, {"source": {"id": "the-times-of-india", "name": "The Times of India"}, "author": "ETMarkets.com", "title": "Buzzing stocks: JPA, Lanco Infra, Axis, RIL,", "description": "Among the 50 stocks in the Nifty index, 25 were in the green and 25 in the red.", "url": "https://economictimes.indiatimes.com/markets/stocks/news/buzzing-stocks-jp-associates-lanco-infratech-axis-bank-ril-bajaj-finance/articleshow/65763736.cms", "urlToImage": "https://img.etimg.com/thumb/msid-65763746,width-1070,height-580,imgsize-117449,overlay-etmarkets/photo.jpg", "publishedAt": "2018-09-11T04:20:30Z", "content": "NEW DELHI: With over 1.70 crore shares changing hands, the counter of Jaiprakash Associates was buzzing as the most traded stock on NSE in morning session on Tuesday. Uttam Value Steels (number of shares traded: 1.35 crore), Lanco Infratech (1.26 crore) and R\u2026 [+1202 chars]"}, {"source": {"id": "the-times-of-india", "name": "The Times of India"}, "author": "ET Now", "title": "Mkt falling? Buy selectively in these 3 spaces: Deven Choksey", "description": "\u201cNot very sure of  a currency play in IT and pharma sectors.\u201d", "url": "https://economictimes.indiatimes.com/markets/expert-view/market-falling-you-could-buy-selectively-in-these-3-spaces-deven-choksey/articleshow/65944443.cms", "urlToImage": "https://img.etimg.com/thumb/msid-65944446,width-1070,height-580,imgsize-399081,overlay-etmarkets/photo.jpg", "publishedAt": "2018-09-25T04:49:19Z", "content": "With oil price zooming, rupee could reach 75-76 level against dollar and that will cause a significant amount of stress, Deven R Choksey, MD, KR Choksey, tells ET Now. Insurance, corporate banks and auto &amp; auto ancillaries have corrected enough and can be\u2026 [+5264 chars]"}, {"source": {"id": null, "name": "Indianexpress.com"}, "author": "PTI", "title": "Sensex, Nifty turn choppy on mixed Asian cues", "description": "Investors turned cautious as trade war concerns between the US and China rose and a persistent weakness in the rupee became lingering concerns leading to volatility in the market, brokers said.", "url": "https://indianexpress.com/article/business/sensex-nifty-turn-choppy-on-mixed-asian-cues-5350193/", "urlToImage": "https://images.indianexpress.com/2018/07/bse-sensex-759.jpg?w=759", "publishedAt": "2018-09-11T06:46:18Z", "content": "By: PTI | Mumbai | Published: September 11, 2018 12:16:18 pm Top gainers include Axis Bank, Infosys, Adani Ports, Sun Pharma, M&amp;M, SBI and Tata Motors, rising up to 2 per cent. (File photo) The BSE benchmark Sensex Tuesday rose 95 points, but soon turned \u2026 [+1242 chars]"}, {"source": {"id": null, "name": "Nejm.org"}, "author": "Kim Papp, Kenneth Gordon, Diamant Tha\u00e7i, Akimichi Morita, Melinda Gooderham, Peter Foley, Ihab G. Girgis, Sudeep Kundu, Subhashis Banerjee", "title": "Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis", "description": "Original Article from The New England Journal of Medicine \u2014 Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1806382", "urlToImage": "https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/0/nejm.ahead-of-print/nejmoa1806382/20180907/images/img_small/nejmoa1806382_f1.jpeg", "publishedAt": "2018-09-12T06:00:02Z", "content": "Supported by Bristol-Myers Squibb. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. Dr. Papp reports receiving grant support, consulting fees, advisory board fees, and fees for serving on a speakers\u2019 burea\u2026 [+4079 chars]"}, {"source": {"id": null, "name": "Moneycontrol.com"}, "author": null, "title": "Stocks in the news: Strides Pharma, Tata Steel, ICICI Bank, Sun Pharma, KIOCL, RITES, Weizmann Forex", "description": "Stocks in the news: Strides Pharma, Tata Steel, ICICI Bank, Sun Pharma, KIOCL, RITES, Weizmann Forex", "url": "https://www.moneycontrol.com/news/business/stocks/stocks-in-the-news-strides-pharma-tata-steel-icici-bank-sun-pharma-kiocl-rites-weizmann-forex-2964261.html", "urlToImage": "https://static-news.moneycontrol.com/static-mcnews/2017/03/stocks_BSE_Nifty_Sensex__bse_nifty-1_1280-770x433.jpg", "publishedAt": "2018-09-19T02:23:40Z", "content": "Here are the stocks that are in news today: SEBI lowers IPO listing timeline to T+3 from current T+6 SEBI approves new KYC norms for FPIs ICICI Bank : The bank in clarification note said it has not filed any application for settlement after certain media repo\u2026 [+5706 chars]"}, {"source": {"id": "the-times-of-india", "name": "The Times of India"}, "author": "ET Now", "title": "'Buy pharma as a bucket, be stock-specific in auto sector'", "description": "\u201cRemain bullish on some of the consumption-related stocks which have been beaten down.\u201d", "url": "https://economictimes.indiatimes.com/markets/expert-view/buy-pharma-as-a-bucket-be-stock-specific-in-auto-sudip-bandyopadhyay-inditrade-capital/articleshow/65729844.cms", "urlToImage": "https://img.etimg.com/thumb/msid-65729851,width-1070,height-580,imgsize-24478,overlay-etmarkets/photo.jpg", "publishedAt": "2018-09-08T06:14:30Z", "content": "The market is not crashing anytime soon. However, it is not going to move up sharply in a hurry either, Sudip Bandyopadhyay, Group Chairman, Inditrade Capital, tells ET Now. Edited excerpts: Do you believe that we can hold our head above the 10,600 mark? What\u2026 [+5456 chars]"}, {"source": {"id": "the-times-of-india", "name": "The Times of India"}, "author": "PTI", "title": "Markets stage relief rally on value-buying", "description": "\u200b\u200bThe session was marked by high volatility and stock-specific action.", "url": "https://economictimes.indiatimes.com/markets/stocks/news/markets-stage-relief-rally-on-value-buying-ril-leads-recovery/articleshow/65714921.cms", "urlToImage": "https://img.etimg.com/thumb/msid-65714915,width-1070,height-580,imgsize-155561,overlay-etmarkets/photo.jpg", "publishedAt": "2018-09-07T04:20:06Z", "content": "MUMBAI: Markets staged a strong comeback on Thursday after six straight sessions of losses as investors accumulated recently hammered healthcare, energy and power stocks even as the rupee breached the 72 level for the first time. The BSE Sensex rebounded 224.\u2026 [+333 chars]"}, {"source": {"id": null, "name": "Indianexpress.com"}, "author": "PTI", "title": "Sensex drops 200 pts on weak global cues; Nifty below 11,550", "description": "The NSE Nifty index too shed 44.50 points, or 0.38 per cent, at 11,544.60.", "url": "https://indianexpress.com/article/business/market/sensex-drops-200-points-on-weak-global-cues-nifty-below-11550-5348171/", "urlToImage": "https://images.indianexpress.com/2018/03/sensex-759.jpg?w=759", "publishedAt": "2018-09-10T05:23:30Z", "content": "By: PTI | Mumbai | Updated: September 10, 2018 10:54:59 am The BSE 30-share barometer fell by 206.85 points, or 0.54 per cent, to 38,182.97 in early trade. The BSE benchmark Sensex dropped 200 points in early deals Monday on negative global cues, widening cur\u2026 [+1875 chars]"}, {"source": {"id": "business-insider", "name": "Business Insider"}, "author": "Lydia Ramsey", "title": "How a Groupon co-founder's experience with a lack of cancer data led him to start a company that's now worth $2 billion after just three years", "description": "Tempus, a cancer care data company, has grown like crazy to a $2 billion valuation. The three-year-old Chicago-based company pulls together data on cancer patients on its platform, including genetic data from tumors and clinical data about how well a patient \u2026", "url": "https://www.businessinsider.com/cancer-data-startup-tempus-now-worth-2-billion-2018-9", "urlToImage": "https://amp.businessinsider.com/images/560159229dd7cc11008bc1bd-1920-960.jpg", "publishedAt": "2018-09-27T18:37:42Z", "content": "Eric Lefkofsky, chief executive officer of biotechnology company Tempus, arrives for a morning session of the annual Allen &amp; Company Sun Valley Conference. Drew Angerer/Getty Images In 2015, the world was just starting to get outraged about drug pricing, \u2026 [+5844 chars]"}, {"source": {"id": null, "name": "Moneycontrol.com"}, "author": null, "title": "Sun Pharma gets USFDA nod for specialty eye drug Xelpros", "description": "Sun Pharma management earlier indicated that the peak sales guidance of Xeplros is expected to be in the range of $50-$75 million over two to three years.", "url": "https://www.moneycontrol.com/news/business/companies/sun-pharma-gets-usfda-nod-for-specialty-eye-drug-xelpros-2949461.html", "urlToImage": "https://static-news.moneycontrol.com/static-mcnews/2018/08/Sun-Pharma-770x433.jpg", "publishedAt": "2018-09-14T03:21:41Z", "content": "Moneycontrol News Sun Pharma, India's largest drug maker on Friday said it got an approval from USFDA for its specialty opthalmic drug Xelpros, which is used to treat chronic eye disease glaucoma. The New Drug Application (NDA) of Xelpros was filed from the H\u2026 [+1860 chars]"}, {"source": {"id": null, "name": "Moneycontrol.com"}, "author": null, "title": "Almirall gets European Commission approval for psoriasis drug : Sun Pharma", "description": "In July 2016, Sun Pharma out-licensed Ilumetri (tildrakizumab) to Almirall, for the development and commercialisation of the product in Europe.", "url": "https://www.moneycontrol.com/news/business/almirall-gets-european-commission-approval-for-psoriasis-drug-sun-pharma-2963311.html", "urlToImage": "https://static-news.moneycontrol.com/static-mcnews/2018/08/Sun-Pharma-770x433.jpg", "publishedAt": "2018-09-18T14:20:05Z", "content": "Sun Pharma said Spanish firm Almirall has received approval from the European Commission (EC) for Ilumetri, a drug used for treating psoriasis. In July 2016, Sun Pharma out-licensed Ilumetri (tildrakizumab) to Almirall, for the development and commercialisati\u2026 [+403 chars]"}, {"source": {"id": null, "name": "Moneycontrol.com"}, "author": null, "title": "Hold Sun Pharma; target of Rs 580: Centrum", "description": "Centrum recommended hold rating on Sun Pharma with a target price of Rs 580 in its research report dated September 17, 2018.", "url": "https://www.moneycontrol.com/news/business/stocks/hold-sun-pharma-target-of-rs-580-centrum-2969031.html", "urlToImage": "https://static-news.moneycontrol.com/static-mcnews/2017/03/hold2-770x433.jpg", "publishedAt": "2018-09-20T10:33:47Z", "content": "Centrum's research report on Sun Pharma We maintain our Hold rating on Sun Pharma (SPIL) with TP of Rs580 (earlier Rs580) based on 26x March\u201920E EPS of Rs22.4. SPIL has developed a strong pipeline of specialty products for the US. It has received US FDA appro\u2026 [+1046 chars]"}, {"source": {"id": null, "name": "Moneycontrol.com"}, "author": null, "title": "Stocks in the news: Sun Pharma, JP Associates, Jai Corp, Essel Propack, Manali Petro", "description": "Sun Pharma | JP Associates | Jai Corp | Essel Propack and Manali Petro are stocks, which are in news today.", "url": "https://www.moneycontrol.com/news/business/stocks/stocks-in-the-news-sun-pharma-jp-associates-jai-corp-essel-propack-manali-petro-2939121.html", "urlToImage": "https://static-news.moneycontrol.com/static-mcnews/2018/02/stocks_markets-770x433.jpg", "publishedAt": "2018-09-11T02:12:29Z", "content": "Here are the stocks that are in news today: Ex-Bonus - GlaxoSmithKline Pharmaceuticals - 1:1 Reliance Home Finance : Q1 profit rises to Rs 48 crore versus Rs 34 crore; revenue increases to Rs 404 crore from Rs 383 crore (YoY). Sun Pharma : One of the wholly o\u2026 [+2199 chars]"}, {"source": {"id": null, "name": "Moneycontrol.com"}, "author": null, "title": "Buy Sun Pharma; target of Rs 790: Motilal Oswal", "description": "Motilal Oswal is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 790 in its research report dated September 19, 2018.", "url": "https://www.moneycontrol.com/news/business/stocks/buy-sun-pharma-target-of-rs-790-motilal-oswal-2-2968511.html", "urlToImage": "https://static-news.moneycontrol.com/static-mcnews/2017/03/BUY_Sell_hold1-770x433.jpg", "publishedAt": "2018-09-20T11:26:59Z", "content": "Motilal Oswal's research report on Sun Pharma The USFDA conducted an inspection at SUNP's Mohali plant during 10-14 September 2018, and issued Form 483 with two observations. We believe SUNP will be able to address these observations with a strong response, a\u2026 [+1312 chars]"}, {"source": {"id": null, "name": "Moneycontrol.com"}, "author": null, "title": "Stocks in the news: Cipla, Wipro, RIL, Sun Pharma, Alembic, Reliance Capital, Redington", "description": "Cipla | Wipro | Sun Pharma | Syngene International | Reliance Capital and Redington are stocks, which are in news today.", "url": "https://www.moneycontrol.com/news/business/stocks/stocks-in-the-news-cipla-wipro-ril-sun-pharma-alembic-reliance-capital-redington-2943471.html", "urlToImage": "https://static-news.moneycontrol.com/static-mcnews/2017/08/sensex_NSE_BSE_Stocks_Stock_market_bse1-770x433.jpg", "publishedAt": "2018-09-12T02:33:05Z", "content": "Here are the stocks that are in news today: Sun Pharma : In its clarification note related to Mohali plant, company said the US FDA is conducting an inspection of Mohali facility (Punjab, India). The inspection started on September 10 and is ongoing. Syngene \u2026 [+4819 chars]"}]}